CETAPRED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CETAPRED (CETAPRED).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
| Metabolism | Hepatic, primarily via CYP3A4. |
| Excretion | Renal (approximately 75% as metabolites, less than 10% unchanged) and fecal (<15%). |
| Half-life | Approximately 2-3 hours for prednisolone; clinical effects persist longer due to receptor-mediated actions. |
| Protein binding | Prednisolone: 90-95% bound primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.6-1.0 L/kg for prednisolone; reflects moderate tissue distribution. |
| Bioavailability | Oral: approximately 70-90%; ophthalmic: systemic absorption minimal but variable. |
| Onset of Action | Oral: 1-2 hours; Ophthalmic: variable, within 1 hour for anti-inflammatory effect. |
| Duration of Action | Ophthalmic: 4-6 hours; systemic effects last 18-36 hours due to genomic actions. |
| Molecular Weight | 404.5 |
Ophthalmic suspension: Instill 1-2 drops into the conjunctival sac every 2-4 hours during the day; may increase to every 1-2 hours for severe inflammation. Periocular injection: 0.5-1 mL (20 mg/mL) as a subconjunctival or retrobulbar injection.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. Prednisolone acetate is primarily cleared via hepatic metabolism; renal excretion of metabolites is minor. |
| Liver impairment | For Child-Pugh class A (mild): No adjustment. Child-Pugh class B (moderate): Reduce dose by 50% or administer every other day. Child-Pugh class C (severe): Avoid use or use with extreme caution; reduce dose by 75%. Prednisolone undergoes hepatic metabolism, and accumulation may occur in severe impairment. |
| Pediatric use | Instill 1 drop into the conjunctival sac every 2-4 hours; may increase to every 1-2 hours if needed. For subconjunctival injection: 0.1-0.5 mL (20 mg/mL) based on age and weight. Use lowest effective dose to minimize systemic effects. |
| Geriatric use | Use the lowest effective dose and shortest duration. Monitor intraocular pressure closely due to increased risk of corticosteroid-induced glaucoma. Consider concurrent use of artificial tears. No specific dose adjustment but caution with systemic absorption. |
| 1st trimester | Use only if potential benefit justifies risk; associated with cleft palate in animal studies, but human data limited. |
| 2nd trimester | Use only if clearly needed; may cause fetal growth restriction and adrenal suppression. |
| 3rd trimester | Avoid prolonged use; may cause neonatal adrenal suppression and hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for CETAPRED (CETAPRED).
| Placental transfer | Crosses placenta; metabolized by placental 11β-HSD2 to less active prednisolone, reducing fetal exposure. |
| Breastfeeding | Excreted in breast milk in low amounts; short-term use considered compatible, but high doses or prolonged use may affect infant adrenal function. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to prednisolone or any componentAdministration of live or live-attenuated vaccines
| Precautions | Immunosuppression and increased infection risk, Adrenal suppression with prolonged use, Osteoporosis with long-term use, Cushing's syndrome with high doses, Growth suppression in children, Ocular effects (cataracts, glaucoma), Psychiatric disturbances, Gastrointestinal perforation risk, Fluid and electrolyte disturbances |
| Food/Dietary | No known food interactions with ophthalmic use. Systemic absorption is minimal, but if accidentally ingested, avoid excessive sodium intake due to sulfacetamide sodium content. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | CETAPRED (betamethasone/prednisolone) is a corticosteroid. First trimester: increased risk of oral clefts (odds ratio ~3.4). Second/third trimester: associated with fetal adrenal suppression, intrauterine growth restriction, and preterm delivery with prolonged use. |
| Fetal Monitoring | Monitor maternal blood pressure, glucose, and electrolytes. Fetal growth ultrasound and biophysical profile recommended. Assess for fetal adrenal insufficiency if prolonged use. |
| Fertility Effects | High doses may disrupt menstrual cyclicity and ovulation; use lowest effective dose. No evidence of permanent infertility. |
| Clinical Pearls |
| Cetapred (prednisolone acetate 0.25% and sulfacetamide sodium 10%) ophthalmic suspension is used for corticosteroid-responsive ocular conditions with concurrent bacterial infection or risk of infection. Shake vigorously before each use. Monitor intraocular pressure (IOP) with use >10 days. Prolonged use may lead to cataract formation, secondary infection, or corneal perforation in diseases causing corneal thinning. Do not use for viral, fungal, or mycobacterial infections. Avoid contamination of dropper tip. |
| Patient Advice | Shake the bottle well before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation and wait at least 15 minutes before reinserting. · Temporary blurred vision may occur; do not drive or operate machinery until vision clears. · Report any eye pain, vision changes, or worsening redness to your doctor immediately. · Do not stop using this medication without consulting your doctor even if symptoms improve. · Keep out of reach of children. Store at room temperature away from light and moisture. |